Therapeutic Targeting of the Gas6/Axl Signaling Pathway in Cancer.

Article Details

Citation
Copy to clipboard

Tanaka M, Siemann DW

Therapeutic Targeting of the Gas6/Axl Signaling Pathway in Cancer.

Int J Mol Sci. 2021 Sep 15;22(18):9953. doi: 10.3390/ijms22189953.

PubMed ID
34576116 [ View in PubMed
]
Abstract

Many signaling pathways are dysregulated in cancer cells and the host tumor microenvironment. Aberrant receptor tyrosine kinase (RTK) pathways promote cancer development, progression, and metastasis. Hence, numerous therapeutic interventions targeting RTKs have been actively pursued. Axl is an RTK that belongs to the Tyro3, Axl, MerTK (TAM) subfamily. Axl binds to a high affinity ligand growth arrest specific 6 (Gas6) that belongs to the vitamin K-dependent family of proteins. The Gas6/Axl signaling pathway has been implicated to promote progression, metastasis, immune evasion, and therapeutic resistance in many cancer types. Therapeutic agents targeting Gas6 and Axl have been developed, and promising results have been observed in both preclinical and clinical settings when such agents are used alone or in combination therapy. This review examines the current state of therapeutics targeting the Gas6/Axl pathway in cancer and discusses Gas6- and Axl-targeting agents that have been evaluated preclinically and clinically.

DrugBank Data that Cites this Article

Drugs